Skip Navigation

EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer NSCLC with Immunobiomarker SIGNature-Driven Analysis

Brief Summary

Type:
Lung Cancers

Study Type:
Treatment

Phase:
II/III

ClinicalTrials.gov Identifier:
NCT03793179

Study #:
STUDY00143897

Start Date:
Jun 17, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03793179

View Complete Trial Details & Eligibility at ClinicalTrials.gov